Why the study?
Does omapatrilat improve cardiorenal functional and structural parameters compared to fosinopril or no treatment in hypertensive transgenic m(Ren-2)27 rats?
Population
40 male transgenic m27 rats at 6 weeks of age exhibiting fulminant hypertension and severe organ pathology
Comparison
Omapatrilat 10 mg/kg/day or 40 mg/kg/day by… vs No treatment or the ACE inhibitor fosinopril 10…
Design
Preclinical, randomized
Follow-up
24 weeks
Authors
Loading...
Preclinical BP superiority of omapatrilat does not inform practice; leaves open human cardiorenal translation.
Does omapatrilat improve cardiorenal functional and structural parameters compared to fosinopril or no treatment in hypertensive transgenic m(Ren-2)27 rats?
In a hypertensive transgenic rat model, omapatrilat provided superior blood pressure reduction and dose-dependent reduction in cardiac hypertrophy compared to fosinopril, while offering similar attenuation of albuminuria and cardiorenal fibrosis.
Burrell et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: